Biotech Values

[Mufaso]

I get your point on not allowing dose adjustment they did titrate up over 4 weeks on the largest of 2.4 mg for which they saw the most efficacy. (started at 0.6, and then went 1.2,1.8, 1.8 ending at 2.4). I would have thought this titration would have alleviated some of the AE's. I'm not sure how many AE's might have been averted by dose adjustment but have to believe some would have been. ALT didn't release any data on when the AE's occurred for the 2.4 mg cohort as far as I can see which would have helped in understanding if dose adjustment could have made a significant difference.

On slide 17 they show AE's and 51.5% of the subjects had Nausea while 27.8% had Vomiting for the 2.4 mg arm. Comparing the 24 mg dose to the 1.8 mg dose shows the titration may have helped some (59.6% nausea, 27.3% Vomiting in the 1.8mg arm) but not much.

I will say that ALT's Momentum for Permvidutide was a reasonably large phase 2 with n= around 100 in each arm and that the weight loss at the highest dose was impressive/not peaking at 48 weeks. Also, the lipids numbers were very good as you say. As far as the share price goes, one could hold out hope that a better titration plan and or dose adjustment might prove valuable and make the drug competitive. It's given the shorts or possible investors something to ponder and reason for the stock to partially recover to somewhere near the pre phase 1 share price. Still a no go for me though with the Glucagon component being of the most concern.